

PATENT #15 V

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ppincants

Abuljadayel

Serial No.

09/853,188

Filed

May 9, 2001

Examiner

Canella

**Group Art Unit** 

1642

For

A Device

745 Fifth Avenue New York, NY 10151

MECEIVED

MAR 03 2004

EXPRESS MAIL

Mailing Label Number: 2018/2018/2019

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR 1.10 on the date indicated above and is addressed to: Mail Stop Petition, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Warres Jackson

(Typed or printed name of person mailing paper or fee)

(Signature of person mailing paper or fee)

## PETITION TO WITHDRAW HOLDING OF ABANDONMENT UNDER 37 CFR 1.181(a)

#### **Mail Stop Petition**

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

#### Dear Sir:

This Petition for Withdrawal of the Holding of Abandonment is being filed in response to the Notice of Abandonment rendered on February 19, 2004. The Notice states that Applicant failed to timely file a proper reply to the Office Action mailed on June 3, 2003, and further states that no reply was received.

Applicants wish to respectfully bring to the Commsioner's attention the fact that a response to the June 3, 2003 was indeed timely filed. Attached hereto please find a copy of the response filed on October 3, 2003, the Express Mail receipt, and the postcard receipt returned to us bearing a USPTO date stamp indicating the date of October 3, 2003.

00178282

1

In light of the above, petitioner respectfully requests that the Commissioner withdraw the Holding of Abandonment on this application so that the prosecution of this application be allowed to continue.

It is believed that no fees are required for this Petition. However, in the event that any fees are deemed to be due, the Commissioner is hereby authorized to charge any such fee to Deposit Account No. 50-0320.

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP Attorneys for Applicants

By:

Thomas J. Kowalski Reg. No. 32,147

Tel (212) 588-0800 Fax (212) 588-0500

Email TKowalski@FLHLaw.com

2 00178282

Mailech L#EV28782019145 on 10/3/03 File No. 674528-2003 1 By TJK AMNISCH Serial No. 09 Title in the Matter of the Application of Applicant(s)/Inventor(s) Abulgadage!

The following due in the U.S. Patent Office, was received in the Patent Office MAR OS ROLLING □ Declaration Express Mail Mailing Label # EV28782019 45 O Amendment. (separate sheet) Preliminary Amendment Check No. 028 574 for \$ 475.00 Check No. \_\_\_\_\_\_\_
Deposit Account Order Form Amendment After Final Rejection ☐ Request for Extension of Time O Drawing\_ Sheet(s) ☐ Provisional Patent Application Information Disclosure Statement Application for Patent, including PTO Form 1449 Pages Specification ☐ Issue Fee/Publication Fee Transmittal Abstract □ Declaration O Oath □ Power O Appeal Brief (triplicate) Request for Filing Continuation or Divisional Application for TM Registration Application sheets Including Specimens □ PCT Request □ Status Request sheets, including ☐ Notice of Appeal (triplicate) □ Transmittal Letter Petition □ Response □ Request for Continued Exam (RCE) ☐ Priority Document Assignment ☐ Recordation Cover Sheet Statement of Use □ Amendment Fee Transmittal Response to Examiner's Statement Claim of Priority Search Report D Request for Approval of Drawings D Response to Notice to File Missing Parts

Response to Office Action with O Diskette with Sequence Listing Regnest for withdrawal of Restriction Real and Election Species and Kebyest For Eot

Mailed Via Exp. Mail# EV28782019145 on 10/3/03 Serial No. 09/853 180
Title in the Matter of the Application of Applicant(s)/Inventor(s) Abuly A Device By TJK AMAISCH The following due ffice, was received in the Patent Office □ Affidavit Seclaration Ameridment
 Preliminary Amendment Express Mail Mailing Label # EV28782019 45 (separate sheet) ☐ Ame dment After Final Rejection☐ Request for Extension of Times Check No. 028 574 Deposit Account Order Form Provisional Patent Application Drawing \_ Sheet(s) Application for Patent, including Information Disclosure Statement Pages Specification PTO Form 1449 Declaration ☐ Issue Fee/Publication Fee Transmittal O Oath Request for Filing Continuation or Divisional Appeal Brief (triplicate) Application \_ Application for TM Registration \_ sheets □ PCT Request Including . sheets, including Specimens Transmittal Letter Status Request ☐ Notice of Appeal (triplicate) □ Request for Continued Exam (RCE) 0 Petition Response Assignment Priority Document ☐ Recordation Cover Sheet ☐ Amendment Fee Transmittal Statement of Use ☐ Claim of Priority Response to Examiner's Statement Request for Approval of Drawings ☐ Search Report Response to Notice to File Missing Parts

Response to Office Action Diskette with Sequence Listing Request for vitudra. Restriction Real and Election Secres and Leavest For Lot

ومنعقها والمعادية فأمانا



(C)

 $\odot$ 

Mailing Label

0

**5**)?

12!

EXPRESS MAIL

DELIVERY (POSTAL SERVICE 
DELIVERY (POSTAL USE ONLY)

Delivery Attempt Time Employee Signature

Mo. Day AM PM

Delivery Date Time Employee Signature

Mo. Day AM PM

Delivery Date Time Employee Signature

Mo. Day AM PM

Way Figure Signature

Mo. Day AM PM

Employee Signature

Mo. Day AM PM

Way Figure Signature

Mo. Day AM PM

Way Figure Signature

Mo. Day AM PM

Way Figure Signature

Mo. Day AM PM

| September | New York | New York

FROM: PLEASE PRINT)
PHONE:
FROMMER LAWRENCE & HAUG, LLP
745 5TH AVE FL 10
NEW YORK
NY 10151-1000

☐ S PM


3rd Da

Hote

674528-2003-1(TKAMN)

Commissioner for Patents P.O. Box 1450 Alexandria, VAZZ313-

|  | ACKING CALL 1-800-222-1811 www.usps.com  |
|--|--|
| EV 287820191 US  | EXPRESS Customer Copy Label 11-F June 2002   |
| ORIGIN (POSTAL USE ONLY)  Po ZIP Code  Deay of Delivery  Plat Rate Envelope  Date In  Postal In  | UNITED STATES DOG  |
| Date in Next Second   Next Sec | DELIVERY (POSTAL USE ONLY)  Delivery Attempt  Time  Mo: Day  |
| AM Return Receipt Fee sight Sid Day Sid Day Int'l Alpha Country Code   | Mo Day AM PM Signature   |
| Delivery Oze Insurance Fee Ins | Mo. Day  WANVERIORSIONATURE (incompanished) Modification and under a second control of the contr |
| 1 Mai Corporate Acct. No.  2.1 | Colored Continuo Direction and Continuo Colored Colore |
| OMMER LAWRENCE & HALL  | Footral Agoncy Acet. No. or CIBEOTRANSCORDER  TO: (PLEASE PRINT)   |
| NY 10151-1000  | Commissioner for Pate 1  |
| 74528-202  | 10 BOX 1450  |
| ABD  | Alexandria, VAZZ313-   |
| sking 3 copies. FOR PICKUP OR TRACKING CALL 1-800-22   | 2-1811 www.usps.com  |



| TVAILE OF CELETY OF ACCOUNT | FILE NO.   | ALTORNET | AMOUNT |
|-----------------------------|------------|----------|--------|
| 6745 <del>08-2</del>        | 15006-8051 | TJK/AMN  | 475 —  |
| Tristem/Morrison & Foerster |            |          |        |
|                             |            |          |        |
|                             |            |          |        |
|                             |            |          |        |
|                             |            |          |        |
|                             |            |          |        |

RECEIVED
MAR 03 2004

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**Applicants** 

Serial No.

Filed

Examiner

Group Art Unit

For

Abuljadayel

09/853,180

May 9, 2001

Canella

1642

A Device

745 Fifth Avenue, New York, New York 10151

**EXPRESS MAIL** 

Mailing Label Number:

EV287820191

Date of Deposit:

October 3, 2003

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR 1.10 on the date indicated above and is addressed to: Mail Stop 313(c), Commissioner for Patents,

P.O. Box 1450, Alexandria, VA 22313-1450.

(Typed or printed name of person mailing paper or fee)

(Signature of person mailing paper or fee)

RESPONSE TO OFFICE ACTION WITH REQUESTS FOR WITHDRAWAL OF RESTRICTION REQUIREMENT AND ELECTION OF SPECIES AND REQUEST FOR EXTENSION OF TIME

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In response to the Office Action mailed June 3, 2003, setting a one-month period for response and requiring restriction and an election of species, Applicants elect with traverse, Group I; Hematopoietic cells from Group A; CD34<sup>+</sup> cell surface marker from Group B; and CFC-T cells and T-cells from Group C. Pursuant to 37 C.F.R. §§ 1.136(a) and 1.17(a), a three-month extension of the period for reply, i.e., to up to and including October 3, 2003 is requested. Enclosed is a check in the amount of \$475.00 in payment of the fee therefore by a small entity. The Commissioner is hereby authorized to charge any additional fees, or credit any overpayment in fees, to Deposit Account 50-0320.

#### **REMARKS**

Reconsideration and withdrawal of the Office Action requiring restriction and an election of species is respectfully requested in view of the remarks herewith.

### I. RESPONSE TO RESTRICTION REQUIREMENT

The June 3, 2003 Office Action required restriction from among the following Groups under 35 U.S.C. §121:

Group I: Claims 1-41, drawn to a device for forming or increasing the relative

number of undifferentiated cells in a cell population, classified in class

435, subclass 284.1;

Group II: Claims 42-97, drawn to a method for preparing an undifferentiated cell

comprising retro-differentiating a more committed cell to a less committed

cell, classified in class 435, subclass 377; and,

Group III: Claims 98-100, drawn to a business method comprising supplying a

device as claimed in any of claims 1-4 and/or means that are capable of

causing a committed cell to retro-differentiate into an undifferentiated cell.

classified in class 705, subclass 500.

Applicants elect Group I, with traverse.

The Office Action alleges that the claims of Group I and Group II constitute distinct inventions because they are related as process and apparatus for its practice. Under MPEP §806.05(e) inventions related as process and apparatus for its practice are distinct if it can be shown that either (1) the process as claimed can be practiced by another materially different process or by hand, or (2) the apparatus as claimed can be used to practice another materially different process. The Office Action asserts that in this case the apparatus of Group I can be used for the materially different process of preparing a transformed cell line.

Similarly, the Office Action alleges that the claims of Groups I and III are distinct inventions because they are related as product and process of use. Under MPEP §806.05(h), inventions related as product and process of use may be found to be distinct if it can be shown that either (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different

process of using that product. In the instant case, it is alleged that the device of Group I can be used in the method of Group II or of Group III.

Additionally, it is alleged that the claims of Groups II and III are distinct because the methods of Groups II and III differ in the method objectives, method steps and parameters and in the reagents and supplies used.

Further, the Restriction Requirement maintains that "[b]ecause these inventions are distinct ... and have acquired a separate status in the art because of their recognized divergent subject matter, different classification, and different search requirements, restriction for examination purposes as indicated is proper." Office Action at 3.

It is respectfully requested that the Restriction Requirement be reconsidered and withdrawn, and Groups I, II and III be rejoined such that claims 1-100 are searched and examined together, or at the very least, that Groups I and II be rejoined, such that claims 1-97 are searched and examined together.

The Office Action asserted that the apparatus of Group I can be used to practice the materially different process of preparing a transformed cell line. However, it is respectfully submitted that the preparation of a transformed cell line is not a materially different process, and that, in fact, the use of the apparatus to prepare a transformed cell line falls within the scope of Group I as claimed. Group I relates to a device for increasing the relative number of undifferentiated cells in a population. It is respectfully submitted that undifferentiated cells may comprise transformed cells. The process of transformation in relation to animal cells refers to "the acquisition of cancer like properties" following treatment with an agent (Alberts et al., Molecular Biology of the Cell. Third Edition, 1994). One of the defining features of cancer cells is their ability to proliferate at a higher rate than their neighbors thus giving rise to a tumor. Alberts et al., states that "if a transformed cell is to generate a steadily growing clone of progeny ... the process of differentiation must be deranged so that ... cells retain an ability to carry on dividing indefinitely;" i.e. if a differentiated slowly proliferating or non-proliferating cell is to be transformed, there must be some dedifferentiation to a more primitive proliferative state. Thus, many transformed cells are also undifferentiated cells.

Furthermore, it is respectfully submitted that the claims of Group I and Group II and both classified in class 435, providing further evidence that the search and examination of either group would be likely co-extensive.

In light of the above, it is respectfully submitted that the use of the apparatus of Group I to prepare a transformed cell line does not constitute a materially different process to the claimed use of the apparatus, and thus, the assertion that Group I and Group II are distinct is not proper.

Similarly, the Office Action alleges that the claims of Groups I and III are distinct inventions because they are related as product and process of use, and the device of Group I can be used in the method of Group II or of Group III. It is respectfully submitted that the Claims of Group III are dependent on claims classified in Group I, thereby demonstrating the interrelatedness of Group I and III, such that any search and examination of the Groups would be co-extensive.

Additionally, it is alleged that the claims of Groups II and III are distinct because the methods of Groups II and III differ in the method objectives, method steps and parameters and in the reagents and supplies used. Applicants respectfully disagree. The claims are all directed towards preparation of an undifferentiated cell, or to increasing the relative number of undifferentiated cells in a population of cells, such that any search and examination of Groups II and III are likely to be co-extensive.

In further traverse, it is noted that the MPEP lists two criteria for a proper restriction requirement. First, the inventions must be independent or distinct (MPEP § 803). Second, searching the additional inventions must constitute an undue burden on the examiner if restriction is not required. Under Patent Office examining procedures, "[i]f the search and examination of an entire application can be made without serious burden, the Examiner must examine it on the merits, even though it includes claims to distinct or independent inventions" (MPEP § 803) (emphasis added).

The present invention relates to, *inter alia*, methods of preparing undifferentiated cells by retro differentiating more committed cells into less committed cells. It is respectfully asserted that the Office Action, in defining the subject matter of Group I, fails to recognize that the device provides a method of increasing the relative number of cells in a population by retro-differentiating more committed cells into less committed cells. Thus, a search of the claims of Group I would consequently and inextricably encompass a search of the claims included in Groups II and III and vice versa. For example, claims 19-22 in Group I and claims 44-49 in Group II are directed to sources of committed cells, claim 39 in Group I and claim 43 in Group II are directed to use of buffy coat blood samples, claims 23-26 in Group I and claims 50-53 in

Group II are directed to types of undifferentiated cells produced by retro differentiation of committed cells, claims 28-32 in Group I and claims 55-59 in Group II are directed to receptors that mediate capture, recognition or presentation of antigens at the surface of the committed cells, and claims 33-38 in Group I and claims 60-64 in Group 2 are directed to retro differentiation agents. Thus, examination of either Group I or Group II mandates consideration of the patentable elements in the other Group. And, as the claims of Group III are dependent on claims in Group I, the search of Group I would also be interrelated with that of Group III. Indeed, the search and examination of each Group is likely to be co-extensive and, in any event, would involve such interrelated art that the search and examination of the entire application can be made without undue burden on the Examiner.

Thus, restriction has not been shown to be proper, especially since the requisite showing of serious burden has not been made in the Office Action. All of the preceding, therefore, mitigate against restriction. Accordingly, it is respectfully requested that the restriction requirement be reconsidered and withdrawn.

#### II. RESPONSE TO ELECTION REQUIREMENT

The June 3, 2003 Office Action further required an election of species at pages 3-4. Hematopoietic cells from Group A, CD34<sup>+</sup> cell surface marker from Group B, and CFC-T cells and T-cells from Group C, are hereby elected, with traverse. It is understood that the election of species is only for search and examination purposes, and that it can be expanded to ultimately encompass generic claims such as claim 1 upon determination of allowable subject matter. As will be shown below, species (i) and (ii) of Group C should be rejoined, such that Applicants elect CFC T-cells and T-cells, and CFC B-cells and B-cells.

The Office Action alleges that the application contains claims directed to patentably distinct species of the claimed invention and therefore requires an election of species. However, the requirement of species election is requested without appropriate or due reason. The Examiner states that "Applicant is required under 35 U.S.C. 121 to elect a single disclosed species..." but fails to provide support as to the reason why the members of each species are patentably distinct. Office Action at 4.

In further traverse, a claim reciting all species of Group C has previously been deemed allowable subject matter, as evidenced by claim 16 of U.S. Patent No. 6,090,625.

Further, as the species are not too many in number, it is respectfully submitted that the Examiner must search and examine them together, as MPEP 803.02 specifically provides that members of a *Markush* group must be searched and examined together, if they are not too many in number. Moreover, the examination of the elected species can be extended to the non-elected species.

Therefore, it is respectfully submitted that the election of species requirement should be reconsidered and withdrawn because the species set forth in the claims are sufficiently few in number such that a search and examination thereof can be made without serious burden to the Examiner, and a claim reciting all species of Group C has previously been deemed allowable.

At the very least, it is respectfully requested that the applicants be permitted to elect two species of Group C, namely species (i) CFC T-cells and T-cells, and species (ii) CFC B-cells and B-cells. It is accepted in the art that T-cells and B-cells are closely related, as both are lymphocytes and both function in antigen recognition. Further, it is USPTO practice to recite T-cells and B-cells as members of a single claim, as evidenced by US patents 5,620,689, 5,646,251 and 6,045,788. Therefore, reconsideration and withdrawal of the required election of species is respectfully requested, or, in the alternative, it is respectfully requested that species (i) and (ii) of Group C be rejoined, such that CFC T-cells and T-cells are searched and examined with CFC B-cells and B-cells.

#### **CONCLUSION**

Enforcing the present restriction and election of species requirements would result in inefficiencies and unnecessary expenditures by both the Applicants and the PTO, as well as extreme prejudice to Applicants (particularly in view of GATT, a shortened patent term may result in any divisional or continuing applications filed).

Further, restriction has not been shown to be proper, especially since the requisite showing of serious burden has not been made. Indeed, the search and examination of each Group and species is likely to be co-extensive and, in any event, would involve such interrelated art that the search and examination of the entire application can be made without undue burden on the Examiner.

All of the preceding remarks, therefore, mitigate against restriction. In view of the foregoing, reconsideration and withdrawal of the restriction and election of species requirements

and favorable examination of all the claims of Groups I, II and III on the merits are respectfully requested.

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP

Attorneys for Applicants

By:

Thomas J. Kowalski

Reg. No. 32,147

Angela M. Nigro-Collison

Reg. No. 51,107

Tel (212) 588-0800

Fax (212) 588-0500

Email TKowalski@FLHLaw.com



UNITED STATES DEPARTMENT OF CON Patent and Trademark Office ASSETANT SECRETARY AND COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 2023 1

GAU 1642

SN 09853188

Date:

03/02

To:

Group Directors/HSAEs

From:

Office of Initial Patent Examination

Subject:

Miscellaneous Papers

The attached papers belong in files that are housed at the warehouse. PLEASE do not send any papers to the warehouse or to our office for processing, but request the files from the warehouse and take the appropriate action.

Thank You,

**OIPE**